Logo image of HIT

HEALTH IN TECH INC-CLASS A (HIT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HIT - US42217D1028 - Common Stock

1.43 USD
+0.03 (+2.14%)
Last: 1/16/2026, 8:25:33 PM
1.43 USD
0 (0%)
After Hours: 1/16/2026, 8:25:33 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to HIT. HIT was compared to 148 industry peers in the Insurance industry. HIT has a great financial health rating, but its profitability evaluates not so good. HIT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year HIT was profitable.
  • HIT had a positive operating cash flow in the past year.
HIT Yearly Net Income VS EBIT VS OCF VS FCFHIT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 1M 2M 3M

1.2 Ratios

  • HIT has a Return On Assets of 6.32%. This is amongst the best in the industry. HIT outperforms 89.04% of its industry peers.
  • The Return On Equity of HIT (8.38%) is worse than 60.27% of its industry peers.
  • HIT has a Return On Invested Capital of 5.83%. This is amongst the best in the industry. HIT outperforms 84.25% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for HIT is below the industry average of 15.11%.
  • The last Return On Invested Capital (5.83%) for HIT is well below the 3 year average (12.86%), which needs to be investigated, but indicates that HIT had better years and this may not be a problem.
Industry RankSector Rank
ROA 6.32%
ROE 8.38%
ROIC 5.83%
ROA(3y)8.69%
ROA(5y)N/A
ROE(3y)15.98%
ROE(5y)N/A
ROIC(3y)12.86%
ROIC(5y)N/A
HIT Yearly ROA, ROE, ROICHIT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 10 20 30 40

1.3 Margins

  • With a Profit Margin value of 4.68%, HIT is not doing good in the industry: 67.81% of the companies in the same industry are doing better.
  • HIT has a Operating Margin of 4.50%. This is amonst the worse of the industry: HIT underperforms 80.82% of its industry peers.
  • HIT has a Gross Margin of 67.07%. This is amongst the best in the industry. HIT outperforms 97.26% of its industry peers.
Industry RankSector Rank
OM 4.5%
PM (TTM) 4.68%
GM 67.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HIT Yearly Profit, Operating, Gross MarginsHIT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 20 40 60 80

9

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), HIT is creating some value.
  • HIT has more shares outstanding than it did 1 year ago.
  • There is no outstanding debt for HIT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HIT Yearly Shares OutstandingHIT Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
HIT Yearly Total Debt VS Total AssetsHIT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • HIT has an Altman-Z score of 10.95. This indicates that HIT is financially healthy and has little risk of bankruptcy at the moment.
  • HIT's Altman-Z score of 10.95 is amongst the best of the industry. HIT outperforms 99.32% of its industry peers.
  • HIT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.95
ROIC/WACC0.66
WACC8.83%
HIT Yearly LT Debt VS Equity VS FCFHIT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 2M 4M 6M 8M 10M

2.3 Liquidity

  • HIT has a Current Ratio of 2.87. This indicates that HIT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.87, HIT belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
  • HIT has a Quick Ratio of 2.87. This indicates that HIT is financially healthy and has no problem in meeting its short term obligations.
  • HIT has a better Quick ratio (2.87) than 91.10% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.87
HIT Yearly Current Assets VS Current LiabilitesHIT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M 20M 25M

3

3. Growth

3.1 Past

  • The earnings per share for HIT have decreased strongly by -55.43% in the last year.
  • HIT shows a decrease in Revenue. In the last year, the revenue decreased by -8.93%.
EPS 1Y (TTM)-55.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
Revenue 1Y (TTM)-8.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%90.41%

3.2 Future

  • Based on estimates for the next years, HIT will show a very strong growth in Earnings Per Share. The EPS will grow by 179.42% on average per year.
  • HIT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 60.73% yearly.
EPS Next Y21.2%
EPS Next 2Y27.12%
EPS Next 3Y179.42%
EPS Next 5YN/A
Revenue Next Year67.75%
Revenue Next 2Y47.57%
Revenue Next 3Y60.73%
Revenue Next 5YN/A

3.3 Evolution

HIT Yearly Revenue VS EstimatesHIT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
HIT Yearly EPS VS EstimatesHIT Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0.05 0.1 0.15 0.2 0.25

1

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 71.50, HIT can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, HIT is valued expensively inside the industry as 80.14% of the companies are valued cheaper.
  • Compared to an average S&P500 Price/Earnings ratio of 27.47, HIT is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 70.79, the valuation of HIT can be described as expensive.
  • Based on the Price/Forward Earnings ratio, HIT is valued a bit more expensive than the industry average as 79.45% of the companies are valued more cheaply.
  • When comparing the Price/Forward Earnings ratio of HIT to the average of the S&P500 Index (24.26), we can say HIT is valued expensively.
Industry RankSector Rank
PE 71.5
Fwd PE 70.79
HIT Price Earnings VS Forward Price EarningsHIT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HIT is valued a bit more expensive than the industry average as 71.92% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 35.67
HIT Per share dataHIT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2 0.3 0.4 0.5

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates HIT does not grow enough to justify the current Price/Earnings ratio.
  • HIT's earnings are expected to grow with 179.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.37
PEG (5Y)N/A
EPS Next 2Y27.12%
EPS Next 3Y179.42%

0

5. Dividend

5.1 Amount

  • No dividends for HIT!.
Industry RankSector Rank
Dividend Yield 0%

HEALTH IN TECH INC-CLASS A

NASDAQ:HIT (1/16/2026, 8:25:33 PM)

After market: 1.43 0 (0%)

1.43

+0.03 (+2.14%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupInsurance
GICS IndustryInsurance
Earnings (Last)11-10
Earnings (Next)03-16
Inst Owners2.58%
Inst Owner Change0%
Ins Owners69.47%
Ins Owner Change7.46%
Market Cap81.38M
Revenue(TTM)30.72M
Net Income(TTM)1.44M
Analysts80
Price Target4.59 (220.98%)
Short Float %0.97%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.99%
Min EPS beat(2)-0.99%
Max EPS beat(2)-0.99%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.53%
Min Revenue beat(2)15.6%
Max Revenue beat(2)23.46%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.13%
PT rev (3m)38.46%
EPS NQ rev (1m)-100%
EPS NQ rev (3m)-100%
EPS NY rev (1m)-62.5%
EPS NY rev (3m)-66.67%
Revenue NQ rev (1m)-11.42%
Revenue NQ rev (3m)-11.42%
Revenue NY rev (1m)-1.34%
Revenue NY rev (3m)-1.34%
Valuation
Industry RankSector Rank
PE 71.5
Fwd PE 70.79
P/S 2.65
P/FCF N/A
P/OCF 37.83
P/B 4.74
P/tB 7.41
EV/EBITDA 35.67
EPS(TTM)0.02
EY1.4%
EPS(NY)0.02
Fwd EY1.41%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0.04
OCFY2.64%
SpS0.54
BVpS0.3
TBVpS0.19
PEG (NY)3.37
PEG (5Y)N/A
Graham Number0.37
Profitability
Industry RankSector Rank
ROA 6.32%
ROE 8.38%
ROCE 7.89%
ROIC 5.83%
ROICexc 10.77%
ROICexgc 30.87%
OM 4.5%
PM (TTM) 4.68%
GM 67.07%
FCFM N/A
ROA(3y)8.69%
ROA(5y)N/A
ROE(3y)15.98%
ROE(5y)N/A
ROIC(3y)12.86%
ROIC(5y)N/A
ROICexc(3y)19.87%
ROICexc(5y)N/A
ROICexgc(3y)65.42%
ROICexgc(5y)N/A
ROCE(3y)20.71%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover1.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 473.62%
Cap/Sales 9.65%
Interest Coverage 250
Cash Conversion 107.09%
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.87
Altman-Z 10.95
F-Score5
WACC8.83%
ROIC/WACC0.66
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)10.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-55.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10%
EPS Next Y21.2%
EPS Next 2Y27.12%
EPS Next 3Y179.42%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%90.41%
Revenue Next Year67.75%
Revenue Next 2Y47.57%
Revenue Next 3Y60.73%
Revenue Next 5YN/A
EBIT growth 1Y-70.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year308.53%
EBIT Next 3Y159.07%
EBIT Next 5YN/A
FCF growth 1Y231.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.34%
OCF growth 3YN/A
OCF growth 5YN/A

HEALTH IN TECH INC-CLASS A / HIT FAQ

What is the ChartMill fundamental rating of HEALTH IN TECH INC-CLASS A (HIT) stock?

ChartMill assigns a fundamental rating of 4 / 10 to HIT.


What is the valuation status of HEALTH IN TECH INC-CLASS A (HIT) stock?

ChartMill assigns a valuation rating of 1 / 10 to HEALTH IN TECH INC-CLASS A (HIT). This can be considered as Overvalued.


What is the profitability of HIT stock?

HEALTH IN TECH INC-CLASS A (HIT) has a profitability rating of 3 / 10.


Can you provide the financial health for HIT stock?

The financial health rating of HEALTH IN TECH INC-CLASS A (HIT) is 9 / 10.


Can you provide the dividend sustainability for HIT stock?

The dividend rating of HEALTH IN TECH INC-CLASS A (HIT) is 0 / 10 and the dividend payout ratio is 0%.